Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Shareholders' Equity

v3.21.1
Note 9 - Shareholders' Equity
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
9.
Shareholders
'
Equity
 
Authorized capital stock
 
The Company has authorized share capital of an unlimited number of voting common shares and the shares do
not
have a stated par value.
 
Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to
one
vote per share at the Company's annual general meeting and any special meeting.
 
Equity issued during the
three
months ended
March 31, 2021
 
During the
three
months ended
March 31, 2021,
40,000
common shares were issued on the exercise of options for gross proceeds of
$244,000
and
no
warrants were exercised.
 
Equity issued during the
three
months ended
March 31, 2020
 
On
February 13, 2020,
we issued and sold an aggregate of
2,125,000
common shares in a public, underwritten offering at a public offering price of
$4.00
per share. As a result of the offering, we received gross proceeds of
$8.5
million, which resulted in net proceeds to us of approximately
$7.7
million, after deducting the underwriting discount and offering expenses.
 
During the
three
months ended
March 31, 2020,
7,200
common shares were issued on the exercise of options for gross proceeds of
$16,000
and
no
warrants were exercised.
 
Shares reserved
 
Common shares reserved for future issuance are as follows:
 
   
March 31, 2021
 
Stock options outstanding
   
1,421,094
 
Deferred share units outstanding
   
72,142
 
Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan
   
1,050,026
 
Common shares issuable under common share purchase warrants
   
265,000
 
Total
   
2,808,262